logo-loader

AstraZeneca wins US approval for cancer drug

Published: 10:25 14 Jul 2015 BST

Astrazeneca-laboratory-testing_opt
AstraZeneca is considering combining Iressa with other medicines

Drug giant AstraZeneca (LON:AZN) has won US permission for a lung cancer treatment.

The group said the US Food & Drug Administration had approved Iressa (gefitinib) tablets for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC).

Iressa is approved in 91 countries. AstraZeneca said it was also studying Iressa in combination with other investigational medicines, including the company's anti-PD-L1 monoclonal antibody, durvalumab, as a treatment for a broader range of lung cancer patients.

Head of oncology in global medicine development at AstraZeneca, Antoine Yver, said: "The approval of IRESSA provides physicians and patients in the US with a new choice of first-line treatment for metastatic non-small cell lung cancer."

Shares in AstraZeneca gained 25p to 4,356p.

 

 

 

 

 

 

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

13 minutes ago